Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
1–27
Headlines
27
Sources here
2
Companies here
1
Current section Denmark Drug Manufacturers - General news
Latest

finance.yahoo.com Market update

Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by …

Main company 🇩🇰 Denmark
Read at finance.yahoo.com
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
Just inNext headlines
finance.yahoo.com Earnings Main company 🇩🇰 Denmark

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Main company 🇩🇰 Denmark

Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Chronological news

Latest headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Analyst action Main company 🇩🇰 Denmark

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading

European equities traded in the US as American depositary receipts were edging lower late Wednesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Main company 🇩🇰 Denmark

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Lilly Takes Its Weight-Loss Pill Battle Overseas

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Main company 🇩🇰 Denmark

Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
nasdaq.com Analyst action Main company 🇩🇰 Denmark

NVO Crosses Above Average Analyst Target

In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?

For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough.

Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications. Continue Reading

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

European Stocks Close Mixed in Monday Trading as Investors Monitor Middle East War Developments

The European stock markets closed mixed in Monday trading as investors continue to gauge development PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Inc. -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027-- -- In June …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date

(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that the FDA review of its apitegromab Biologics License Application for spinal Silver Upgrade to read …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Amazon.com Inc.'s Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access. The company announced …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Main company 🇩🇰 Denmark

Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Main company 🇩🇰 Denmark

Novo Nordisk A/S Q2 Earnings Call Highlights

Key Points Interested in Novo Nordisk A/S? Here are five stocks we like better. Novo Nordisk raised its 2026 outlook after a better-than-expected start to the year, reporting Q2 adjusted sales of DKK 78.5 billion and 7% growth at constant exchange rates. However, lower …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish facility as Official Action Indicated (OAI) Scholar Rock continuing to collaborate closely with FDA and …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇩🇰 Denmark

Novo Nordisk Stock Rises After GLP-1 Antitrust Win

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context